ArticleCureus2026
Rhabdomyosarcoma in Children: A Retrospective Analysis of 12 Cases.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study aimed to describe the clinicopathological characteristics, immunohistochemical profile, treatment, and outcomes of 12 pediatric rhabdomyosarcoma (RMS) cases diagnosed at our institution and to compare our findings with those reported in the literature. Materials and methods The study involved a retrospective analysis of 12 cases of histologically confirmed RMS diagnosed between November 2018 and September 2025 at the Department of Anatomical Pathology at the Mohammed VI University Hospital Center in Oujda. Results The sex ratio was 1:1, and the median age at diagnosis was two years and six months. Children aged between one and five years represented eight cases (66.6%). Tumor size exceeded 5 cm in eight patients(66.6%). The most common anatomical location was the head and neck (non-parameningeal) region, accounting for three cases (25%), followed by the orbit, extremities, and bladder, with two cases each (16.7%). The genitourinary tract (excluding the bladder and prostate), abdomen, and trunk each represented one case (8.3%). Embryonal RMS was the predominant histological subtype, accounting for eight cases (66.6%), whereas alveolar RMS and the botryoid variant of embryonal RMS each represented two cases (16.7%). Risk stratification revealed an equal distribution among the four categories, each accounting for three cases (25%): low-risk subset 1, low-risk subset 2, intermediate risk, and high risk. All patients received chemotherapy, whereas five (41.7%) also underwent surgery, and six (50%) received radiotherapy. Conclusions RMS is the third most common pediatric tumor after neuroblastoma and nephroblastoma. Histopathological and immunohistochemical examinations remain essential for accurate diagnosis, tumor classification, and therapeutic decisions. Treatment relies on a multidisciplinary approach combining chemotherapy with surgery and/or radiotherapy based on risk stratification and other prognostic factors. Despite advances in management, RMS remains one of the most common pediatric soft tissue sarcomas and continues to represent a significant therapeutic challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.